Skip to main content
. 2017 May 23;8(34):56714–56725. doi: 10.18632/oncotarget.18083

Figure 3. Kaplan-Meier estimates of PFS in 26 patients with metastatic sites more than 3.

Figure 3

The median PFS of patients treated with MWA plus EGFR-TKIs was 11.3 months (95%CI, 3.1-22.9 months), and those received EGFR-TKIs was 15.1 months (95%CI, 8.1-22.2 months).